MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has
MapLight Therapeutics raised $150 million from investors who believe in their medicine research. When a company raises money like this, it shows investors think the company has promise, but it also means the company needed cash to keep going.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.